402 research outputs found
Recommended from our members
Artificial neural network techniques to investigate potential interactions between biomarkers
High-throughput technologies in biomedical sciences, including gene microarrays, supposed to revolutionise the post-genomic era, have barely met the great expectations they inspired to the biomedical community at first. Current efforts are still focused toward improving the technology, its reproducibility and accuracy. In the meantime, computational techniques for the analysis of the data from these technologies have achieved great progresses and show encouraging results. New approaches have been developed to extract relevant information out from these results. However, important work needs to be further conducted in order to extract even more meaningful and relevant information. These techniques offer great possibilities to explore the overall dynamic held within a living organism. The potential information contained in their output can reveal important leads at deciphering the interconnection, interaction or regulation influences that can exist between several molecules. In front of an increasing interest of the scientific community toward the exploration of these dynamics, some groups have started to develop solutions based on different technologies to extract these information related to interactions. Here we present an Artificial Neural Network-based methodology for the study of interactions in gene transcriptomic data. This will be applied and validated in a breast cancer context
Recommended from our members
Proteomic analysis of biomarkers associated with immunotherapy in murine tumour models
Emergence of proteomics and high-throughput technologies has allowed the identification of protein expression patterns of disease that potentially hold clinical importance in predictive medicine. The analysis of complex data generated by these technologies incorporates the use of computer algorithms for data mining and identification of important protein biomarkers. Such candidate biomarkers can potentially be used for diagnosis, prognosis and monitoring a variety of diseases as well as the prediction of therapy response. Mass spectrometry has been used widely, for the discovery and quantitation of disease associated biomarkers using a variety of samples such as serum and tissue. In particular, matrix assisted laser desorption/ionisation time of flight mass spectrometry (MALDI-TOF MS) has been used to generate proteomic profiles or “fingerprints” from serum to distinguish patients at different clinical stages of disease. Currently, early stage disease is difficult to diagnose in most cancers as current cancer markers have limited sensitivity and specificity. In advanced stage metastatic disease, treatment options are limited, although it is recognised that some patients may benefit from immunotherapy and in particular vaccine therapy. The use of animal models is critical to evaluate the efficacy of immunotherapies and to investigate tumour immunity in general and the mechanisms involved in tumour progression. These models provide an in vivo environment which cannot be reproduced in vitro, which results in more accurate and reliable information on the host response to immunotherapy and the mechanisms involved
Classification of Pulmonary Nodules by Using Hybrid Features
Early detection of pulmonary nodules is extremely important for the diagnosis and treatment of lung cancer. In this study, a new classification approach for pulmonary nodules from CT imagery is presented by using hybrid features. Four different methods are introduced for the proposed system. The overall detection performance is evaluated using various classifiers. The results are compared to similar techniques in the literature by using standard measures. The proposed approach with the hybrid features results in 90.7% classification accuracy (89.6% sensitivity and 87.5% specificity)
Mass spectrometry-based cancer biomarker discovery
The aim of the projects in this thesis was to identify biomarkers for clear cell renal cell carcinomas (ccRCC) and head and neck/oral squamous cell carcinoma (HNOSCC), using quantitative or qualitative proteomics. Comparative analysis of cancerous and normal tissue homogenates, or secretome analysis of cancer cell cultures using liquid chromatography - mass spectrometry (LC-MS) and immunoassay techniques, allowed the identification of different types of biomarkers: diagnostic or prognostic, biofluid- or tissue-based. Chapter 1 of this thesis provides general information on cancer and cancer biomarker discovery. Chapter 2 gives a brief introduction to the techniques used in this work and theories behind them. Chapters 3 - 5 are papers that resulted from the cancer biomarker discovery research performed here, and Chapter 6 contains the conclusions, the author's comments and the final remarks. The papers on the identification of biomarkers for different diseases, to which the author of this thesis contributed, are listed in the Appendix
The 26th Annual Boston University Undergraduate Research (UROP) Abstracts
The file is available to be viewed by anyone in the BU community. To view the file, click on "Login" or the Person icon top-right with your BU Kerberos password. You will then be able to see an option to View.Abstracts for the 2023 UROP Symposium, held at Boston University on October 20, 2023 at GSU Metcalf Ballroom. Cover and logo design by Morgan Danna. Booklet compiled by Molly Power
Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies
Cutaneous melanoma is an aggressive tumor responsible for 90% of mortality related to
skin cancer. In the recent years, the discovery of driving mutations in melanoma has led to
better treatment approaches. The last decade has seen a genomic revolution in the field of
cancer. Such genomic revolution has led to the production of an unprecedented mole of
data. High-throughput genomic technologies have facilitated the genomic, transcriptomic
and epigenomic profiling of several cancers, including melanoma. Nevertheless, there are
a number of newer genomic technologies that have not yet been employed in large
studies. In this article we describe the current classification of cutaneous melanoma, we
review the current knowledge of the main genetic alterations of cutaneous melanoma and
their related impact on targeted therapies, and we describe the most recent highthroughput genomic technologies, highlighting their advantages and disadvantages. We
hope that the current review will also help scientists to identify the most suitable
technology to address melanoma-related relevant questions. The translation of this
knowledge and all actual advancements into the clinical practice will be helpful in
better defining the different molecular subsets of melanoma patients and provide new
tools to address relevant questions on disease management. Genomic technologies
might indeed allow to better predict the biological - and, subsequently, clinical - behavior
for each subset of melanoma patients as well as to even identify all molecular changes in
tumor cell populations during disease evolution toward a real achievement of a
personalized medicine
Clear Cell Renal Cell Carcinoma 2021–2022
Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this tumor make it an exciting meeting point for translational collaboration between clinicians and basic researchers. Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. This tumor is also a good example to investigate the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. A deeper identification of the varied internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizers, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm. Clear cell renal cell carcinoma is also a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway
- …